

## AOCC2022 - Oral Presentation

Submission No.	Presentation No.	Date	Time	Track	Session	Abstract Title
C000085	<b>01-1</b>	June 17	09:00-10:00	Track 3	Oral Presentation 1	Aryl hydrocarbon receptor signals in epithelial cells govern the recruitment and location of Helios + Tregs in the gut.
C000157	<b>01-2</b>	June 17	09:00-10:00	Track 3	Oral Presentation 1	Asymmetric vagal regulation in the maintenance of intestinal regulatory T-helper cells.
C000067	<b>01-3</b>	June 17	09:00-10:00	Track 3	Oral Presentation 1	IL-17-dependent fibroblastic reticular cell training boosts tissue protective mucosal immunity through IL-10-producing B cells
C000010	<b>01-4</b>	June 17	09:00-10:00	Track 3	Oral Presentation 1	Gut microbiome associates with the occurrence of immune-related adverse event and immune-related colitis
C000129	<b>01-5</b>	June 17	09:00-10:00	Track 3	Oral Presentation 1	Intestinal Ultrasound Predicts Disease Behavior Progression in Patients with Crohn's Disease: A Single-center, Retrospective Study
C000208	<b>01-6</b>	June 17	09:00-10:00	Track 3	Oral Presentation 1	Serum Leucine-Rich $\alpha$ 2 Glycoprotein: A Novel Biomarker For Transmural Inflammation in Crohn's Disease
C000019	<b>02-1</b>	June 17	10:45-11:45	Track 3	Oral Presentation 2	Neutrophil restrains intestinal inflammation through regulation of microbial metabolite dimethyl fumarate to orchestrate IEL homeostasis
C000088	<b>02-2</b>	June 17	10:45-11:45	Track 3	Oral Presentation 2	UHRF1-mediated NPY1R gene methylation protects intestinal epithelial cells through activation of CREB signaling
C000181	<b>02-3</b>	June 17	10:45-11:45	Track 3	Oral Presentation 2	The Comprehensive proteomic investigation of Cronkhite-Canada syndrome: possible evidence for pathogenesis
C000071	<b>02-4</b>	June 17	10:45-11:45	Track 3	Oral Presentation 2	Efficacy and Safety of Combination Induction Therapy with Guselkumab and Golimumab in Participants with Moderately-to-Severely Active Ulcerative Colitis
C000142	<b>02-5</b>	June 17	10:45-11:45	Track 3	Oral Presentation 2	Elevated Artificial Sweetener Body Levels are Associated with Crohn's disease. The ENIGMA study.
C000223	<b>02-6</b>	June 17	10:45-11:45	Track 3	Oral Presentation 2	Compositional differences of gut microbiome using taxonomic profiling in patients with ulcerative colitis after treatment with vedolizumab
C000119	<b>03-1</b>	June 17	13:00-14:00	Track 3	Oral Presentation 3	Long-Term Outcomes After Histologic-Endoscopic Mucosal Healing (HEMH): Results from the UNIFI Study in Ulcerative Colitis (UC)
C000184	<b>03-2</b>	June 17	13:00-14:00	Track 3	Oral Presentation 3	Fecal leukocyte esterase strip test results correlated with fecal calprotectin level for inflammatory bowel disease (IBD) patients
C000283	<b>03-3</b>	June 17	13:00-14:00	Track 3	Oral Presentation 3	A universal gut microbiome signature for diagnosis of Crohn's disease
C000170	<b>03-4</b>	June 17	13:00-14:00	Track 3	Oral Presentation 3	Efficacy of treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's disease from the STARTDUST trial
C000292	<b>03-5</b>	June 17	13:00-14:00	Track 3	Oral Presentation 3	Combination of fecal microbiota transplantation and anti-inflammatory diet induces clinical and deep remission in patients with mild-moderate ulcerative colitis
C000090	<b>03-6</b>	June 17	13:00-14:00	Track 3	Oral Presentation 3	The role of serum Leucine-rich alpha-2 glycoprotein in disease monitoring for ulcerative colitis
C000137	<b>04-1</b>	June 17	14:30-15:30	Track 3	Oral Presentation 4	Correlation of histological mucosal healing with long-term clinical and patient-reported outcomes in moderate to severe ulcerative colitis treated with upadacitinib
C000239	<b>04-2</b>	June 17	14:30-15:30	Track 3	Oral Presentation 4	MR Enterography Radiomic Approach Helps for Characterization of Intestinal Fibrosis in Crohn's Disease
C000033	<b>04-3</b>	June 17	14:30-15:30	Track 3	Oral Presentation 4	Schlafen11 is a potential biomarker for mucosal residual inflammation and a target for JAK inhibitor therapy.
C000202	<b>04-4</b>	June 17	14:30-15:30	Track 3	Oral Presentation 4	Optimal timing of assessing improvement in bowel wall thickness by transperineal ultrasonography may differ among induction therapies in ulcerative colitis
C000013	<b>04-5</b>	June 17	14:30-15:30	Track 3	Oral Presentation 4	Venlafaxine as an Adjuvant Therapy for IBD Patients with Anxious and Depressive Symptoms: A Randomized Controlled Trial
C000062	<b>04-6</b>	June 17	14:30-15:30	Track 3	Oral Presentation 4	Risankizumab therapy results in sustained improvements in endoscopic outcomes in patients with moderate-to-severe Crohn's disease: Phase 3 FORTIFY post-hoc analysis
C000179	<b>05-1</b>	June 17	16:00-17:00	Track 3	Oral Presentation 5	The association between mesenteric fat hyperplasia and disease activity in Crohn's disease
C000261	<b>05-2</b>	June 17	16:00-17:00	Track 3	Oral Presentation 5	LONG-TERM CLINICAL EFFECTIVENESS OF USTEKINUMAB IN JAPANESE PATIENTS WITH CROHN'S DISEASE: A RETROSPECTIVE COHORT STUDY
C000084	<b>05-3</b>	June 17	16:00-17:00	Track 3	Oral Presentation 5	Linked color imaging diagnoses mucosal inflammation and predict relapse in UC patients with MES 0.
C000235	<b>05-4</b>	June 17	16:00-17:00	Track 3	Oral Presentation 5	Distinct alterations of fecal microbiotas refer to the efficacy of adalimumab in Crohn's disease
C000054	<b>05-5</b>	June 17	16:00-17:00	Track 3	Oral Presentation 5	Efficacy and safety of long-term treatment with filgotinib 200 mg among patients with ulcerative colitis: an interim analysis of SELECTIONLTE

**AOCC2022 - Oral Presentation**

Submission No.	Presentation No.	Date	Time	Track	Session	Abstract Title
C000118	<b>05-6</b>	June 17	16:00-17:00	Track 3	Oral Presentation 5	The IBD-disk accurately predicts the daily life burden and correlates with disease activity in patients with Inflammatory Bowel Disease
C000183	<b>06-1</b>	June 18	10:45-11:45	Track 3	Oral Presentation 6	Identification of fibroblast heterogeneity in the murine colon by single-cell transcriptome analysis
C000267	<b>06-2</b>	June 18	10:45-11:45	Track 3	Oral Presentation 6	FNDC5/Irisin promotes apoptosis of intestinal epithelial cells and mucosal barrier damage via integrin $\alpha V \beta 5$ -ROS signaling pathway in ulcerative colitis
C000282	<b>06-3</b>	June 18	10:45-11:45	Track 3	Oral Presentation 6	Single-cell expression atlas reveals the cell heterogeneity in creeping fat of CD
C000048	<b>06-4</b>	June 18	10:45-11:45	Track 3	Oral Presentation 6	Stopping 5-ASA in stable UC is not associated with increased risk of relapse: A double-blinded, randomized-controlled trial
C000234	<b>06-5</b>	June 18	10:45-11:45	Track 3	Oral Presentation 6	Identifying patients with Crohn's disease at high risk of primary nonresponse to infliximab using a radiomic-clinical nomogram
C000103	<b>06-6</b>	June 18	10:45-11:45	Track 3	Oral Presentation 6	Analysis of intestinal metabolites and microbiota in patients with ulcerative colitis complicated with toxigenic <i>Clostridium difficile</i> positive
C000015	<b>07-1</b>	June 18	13:00-14:00	Track 3	Oral Presentation 7	Clinical Features and Therapeutic Outcomes of Ulcerative Colitis related Post-operative Enteritis
C000031	<b>07-2</b>	June 18	13:00-14:00	Track 3	Oral Presentation 7	Endoscopic Phenotypes of the J Pouch in Patients with Ulcerative Colitis: A Single-Center Retrospective Cohort Study in Japan
C000036	<b>07-3</b>	June 18	13:00-14:00	Track 3	Oral Presentation 7	Clinical Outcomes after Colorectal Resection for Ulcerative Colitis in the Elderly (Elderly-onset vs. Nonelderly-onset)
C000063	<b>07-4</b>	June 18	13:00-14:00	Track 3	Oral Presentation 7	Risankizumab induces and maintains clinical remission and clinical response in patients with moderate-to-severe Crohn's disease regardless of prior biologic response
C000296	<b>07-5</b>	June 18	13:00-14:00	Track 3	Oral Presentation 7	Artificial intelligence using a convolutional neural network for automatically detecting and locating small intestine diseases in capsule endoscopy images
C000168	<b>07-6</b>	June 18	13:00-14:00	Track 3	Oral Presentation 7	Exposure to systemic antibiotics increases the risk of inflammatory bowel disease in a dose-dependent manner: A population-based case-control study in Korea
C000016	<b>08-1</b>	June 18	14:15-15:15	Track 3	Oral Presentation 8	Identification of a missense variant in TAS2R43 as a susceptibility gene of intestinal Behçet's disease
C000131	<b>08-2</b>	June 18	14:15-15:15	Track 3	Oral Presentation 8	A Bi-directional Mendelian Randomization Analysis Reveals No Causal Relationship between Inflammatory Bowel Disease and COVID-19
C000177	<b>08-3</b>	June 18	14:15-15:15	Track 3	Oral Presentation 8	The association between antigenemia, histology with immunohistochemistry and mucosal PCR in the diagnosis of ulcerative colitis with concomitant cytomegalovirus infection
C000116	<b>08-4</b>	June 18	14:15-15:15	Track 3	Oral Presentation 8	Efficacy and safety of guselkumab maintenance therapy in moderately-to-severely active Crohn's disease (CD) patients: Week 48 analyses from GALAXI-1 Study
C000269	<b>08-5</b>	June 18	14:15-15:15	Track 3	Oral Presentation 8	Histopathological Features of Monogenic Inflammatory Bowel Disease
C000140	<b>08-6</b>	June 18	14:15-15:15	Track 3	Oral Presentation 8	Early prediction of response to induction treatment in ulcerative colitis using leucine-rich $\alpha$ -2-glycoprotein
C000255	<b>09-1</b>	June 18	16:15-17:15	Track 3	Oral Presentation 9	Maternal emulsifier P80 intake induces gut dysbiosis in offspring and increases the susceptibility of colitis in adulthood
C000153	<b>09-2</b>	June 18	16:15-17:15	Track 3	Oral Presentation 9	How Has the Disease Course of Pediatric Ulcerative Colitis Changed Throughout the Biologics Era? A Comparison with the IBSN Study
C000233	<b>09-3</b>	June 18	16:15-17:15	Track 3	Oral Presentation 9	Elucidation of the pathogenesis of very early onset IBD with genetic analysis for the establishment of differential diagnosis techniques
C000053	<b>09-4</b>	June 18	16:15-17:15	Track 3	Oral Presentation 9	Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
C000150	<b>09-5</b>	June 18	16:15-17:15	Track 3	Oral Presentation 9	Dietary Inflammatory Potential Mediated Gut Microbiota and Metabolites Alteration in Crohn's Disease: A Fire-new Perspective
C000229	<b>09-6</b>	June 18	16:15-17:15	Track 3	Oral Presentation 9	Prediction of Postoperative Anastomotic Recurrence in Crohn's Disease Using Preoperative CTE Radiomic Data